{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:21:58Z","timestamp":1792110118360,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40123-025-01163-6","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T02:56:12Z","timestamp":1749005772000},"page":"1723-1737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early Anatomical and Functional Outcomes of Faricimab in Recalcitrant Neovascular Age-Related Macular Degeneration: A Retrospective Real-World Study in an East-Asian Population"],"prefix":"10.1007","volume":"14","author":[{"given":"Yen-An","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Chi","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo-Fang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ting","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tso-Ting","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Hsin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chi","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Pin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-May","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzyy-Chang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"2","key":"1163_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"1163_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. 2024;331(2):147\u201357.","journal-title":"JAMA"},{"issue":"5","key":"1163_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","volume":"120","author":"BG Busbee","year":"2013","unstructured":"Busbee BG, Ho AC, Brown DM, Heier JS, Su\u00f1er IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046\u201356.","journal-title":"Ophthalmology"},{"issue":"1","key":"1163_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193\u2013201.","journal-title":"Ophthalmology"},{"issue":"9","key":"1163_CR5","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/bjophthalmol-2013-304670","volume":"98","author":"M Suzuki","year":"2014","unstructured":"Suzuki M, Nagai N, Izumi-Nagai K, Shinoda H, Koto T, Uchida A, et al. Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Br J Ophthalmol. 2014;98(9):1186\u201391.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1163_CR6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00417-013-2562-6","volume":"252","author":"A Wolf","year":"2014","unstructured":"Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol. 2014;252(4):647\u201355.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1646","key":"1163_CR7","first-page":"45","volume":"64","author":"The Medical Letter","year":"2022","unstructured":"The Medical Letter. Faricimab (Vabysmo) for age-related macular degeneration and diabetic macular edema. Med Lett Drugs Ther. 2022;64(1646):45\u20136.","journal-title":"Med Lett Drugs Ther"},{"issue":"10326","key":"1163_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"issue":"9","key":"1163_CR9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","volume":"138","author":"J Sahni","year":"2020","unstructured":"Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B, Del Valle RM, et al. Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138(9):955\u201363.","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"1163_CR10","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1007\/s00417-023-06071-8","volume":"261","author":"K Takahashi","year":"2023","unstructured":"Takahashi K, Cheung CMG, Iida T, Lai TYY, Ohji M, Yanagi Y, et al. Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-year subgroup analysis of the TENAYA and LUCERNE trials. Graefes Arch Clin Exp Ophthalmol. 2023;261(11):3125\u201337.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"1163_CR11","first-page":"2212","volume":"64","author":"A Warter","year":"2023","unstructured":"Warter A, Galang C, Heinke A, Deussen D, Gerald F, Kalaw P, et al. Use of Faricimab (VABYSMO) for highly treatment resistant CNV in wet-age related macular degeneration. Investig Ophthalmol Vis Sci. 2023;64(8):2212.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"6","key":"1163_CR12","first-page":"e40100","volume":"15","author":"AM Cheng","year":"2023","unstructured":"Cheng AM, Joshi S, Banoub RG, Saddemi J, Chalam KV. Faricimab effectively resolves intraretinal fluid and preserves vision in refractory, recalcitrant, and nonresponsive neovascular age-related macular degeneration. Cureus J Med Sci. 2023;15(6):e40100.","journal-title":"Cureus J Med Sci"},{"issue":"9","key":"1163_CR13","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1136\/bjophthalmol-2020-318672","volume":"106","author":"LM Bulirsch","year":"2022","unstructured":"Bulirsch LM, Sa\u00dfmannshausen M, Nadal J, Liegl R, Thiele S, Holz FG. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br J Ophthalmol. 2022;106(9):1288\u201394.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1163_CR14","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1167\/iovs.05-0981","volume":"47","author":"K Schulze-Bonsel","year":"2006","unstructured":"Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities \u201chand motion\u201d and \u201ccounting fingers\u201d can be quantified with the freiburg visual acuity test. Investig Ophthalmol Vis Sci. 2006;47(3):1236\u201340.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"6","key":"1163_CR15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/biomedicines9060668","volume":"9","author":"M Rispoli","year":"2021","unstructured":"Rispoli M, Eandi CM, Di Antonio L, Kilian R, Montesel A, Savastano MC. Biomarkers in early response to brolucizumab on pigment epithelium detachment associated with exudative age-related macular degeneration. Biomedicines. 2021;9(6):668.","journal-title":"Biomedicines."},{"issue":"5","key":"1163_CR16","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye. 2021;35(5):1305\u201316.","journal-title":"Eye"},{"key":"1163_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/nyas.12726","volume":"1347","author":"A Scholz","year":"2015","unstructured":"Scholz A, Plate KH, Reiss Y. Angiopoietin-2: a multifaceted cytokine that functions in both angiogenesis and inflammation. Ann N Y Acad Sci. 2015;1347:45\u201351.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"1163_CR18","doi-asserted-by":"publisher","first-page":"45081","DOI":"10.1038\/srep45081","volume":"7","author":"DS Ng","year":"2017","unstructured":"Ng DS, Yip YW, Bakthavatsalam M, Chen LJ, Ng TK, Lai TY, et al. Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation. Sci Rep. 2017;7(1):45081.","journal-title":"Sci Rep"},{"key":"1163_CR19","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","volume":"38","author":"GA Borchert","year":"2024","unstructured":"Borchert GA, Kiire CA, Stone NM, Akil H, Gkika T, Fischer MD, et al. Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Eye. 2024;38:3569\u201377.","journal-title":"Eye"},{"issue":"11","key":"1163_CR20","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1001\/archopht.120.11.1435","volume":"120","author":"JL Dunaief","year":"2002","unstructured":"Dunaief JL, Dentchev T, Ying G-S, Milam AH. The role of apoptosis in age-related macular degeneration. Arch Ophthalmol. 2002;120(11):1435\u201342.","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"1163_CR21","first-page":"349","volume":"62","author":"M Linder","year":"2021","unstructured":"Linder M, Foxton R, Uhles S, Revelant F, Lazendic M, Canonica J, et al. Simultaneous Ang-2\/VEGF-A inhibition prevents subretinal fibrosis progression in preclinical mouse models of choroidal neovascularization (CNV). Investig Ophthalmol Vis Sci. 2021;62(8):349.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1163_CR22","doi-asserted-by":"publisher","first-page":"9994098","DOI":"10.1155\/2021\/9994098","volume":"2021","author":"C Metrangolo","year":"2021","unstructured":"Metrangolo C, Donati S, Mazzola M, Fontanel L, Messina W, D\u2019Alterio G, et al. OCT biomarkers in neovascular age-related macular degeneration: a narrative review. J Ophthalmol. 2021;2021:9994098.","journal-title":"J Ophthalmol"},{"issue":"17","key":"1163_CR23","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE stud\u20146 month results. Eye. 2023;37(17):3574\u201381.","journal-title":"Eye"},{"issue":"1","key":"1163_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","volume":"262","author":"K Kataoka","year":"2024","unstructured":"Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, et al. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262(1):43\u201351.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1163_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000455265","volume":"58","author":"J Cunha-Vaz","year":"2017","unstructured":"Cunha-Vaz J. Mechanisms of retinal fluid accumulation and blood-retinal barrier breakdown. Dev Ophthalmol. 2017;58:11\u201320.","journal-title":"Dev Ophthalmol"},{"issue":"13","key":"1163_CR26","doi-asserted-by":"publisher","first-page":"9478","DOI":"10.1167\/iovs.11-8353","volume":"52","author":"KM Ford","year":"2011","unstructured":"Ford KM, Saint-Geniez M, Walshe T, Zahr A, D\u2019Amore PA. Expression and role of VEGF in the adult retinal pigment epithelium. Investig Ophthalmol Vis Sci. 2011;52(13):9478\u201387.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"1","key":"1163_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/eye.2016.208","volume":"31","author":"M Gemenetzi","year":"2017","unstructured":"Gemenetzi M, Lotery AJ, Patel PJ. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. Eye (London). 2017;31(1):1\u20139.","journal-title":"Eye (London)"},{"issue":"1","key":"1163_CR28","doi-asserted-by":"publisher","first-page":"13920","DOI":"10.1038\/s41598-024-63565-z","volume":"14","author":"S Im","year":"2024","unstructured":"Im S, Song MH, Elangovan M, Woo KM, Park WJ. The matricellular protein CCN5 prevents anti-VEGF drug-induced epithelial-mesenchymal transition of retinal pigment epithelium. Sci Rep. 2024;14(1):13920.","journal-title":"Sci Rep"},{"issue":"5","key":"1163_CR29","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/pharmaceutics15051413","volume":"15","author":"L Ferro Desideri","year":"2023","unstructured":"Ferro Desideri L, Traverso CE, Nicol\u00f2 M, Munk MR. Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration. Pharmaceutics. 2023;15(5):1413.","journal-title":"Pharmaceutics"},{"issue":"6","key":"1163_CR30","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1172\/JCI46322","volume":"121","author":"M Jeansson","year":"2011","unstructured":"Jeansson M, Gawlik A, Anderson G, Li C, Kerjaschki D, Henkelman M, et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Investig. 2011;121(6):2278\u201389.","journal-title":"J Clin Investig"},{"issue":"9","key":"1163_CR31","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3390\/diagnostics14090901","volume":"14","author":"M Brinkmann","year":"2024","unstructured":"Brinkmann M, Viggiano P, Boscia G, Danckwardt M, Susantija E, M\u00fcller T, et al. Analysis of choriocapillaris reperfusion topography following faricimab treatment for neovascular age-related macular degeneration in non-treatment-na\u00efve patients. Diagnostics. 2024;14(9):901.","journal-title":"Diagnostics"},{"key":"1163_CR32","doi-asserted-by":"publisher","first-page":"1411278","DOI":"10.3389\/fmed.2024.1411278","volume":"11","author":"S Cheng","year":"2024","unstructured":"Cheng S, Zhang S, Huang M, Liu Y, Zou X, Chen X, et al. Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications. Front Med (Lausanne). 2024;11:1411278.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"1163_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/IAE.0000000000003283","volume":"42","author":"V Chaudhary","year":"2022","unstructured":"Chaudhary V, Matonti F, Zarranz-Ventura J, Stewart MW. Impact of fluid compartments on functional outcomes for patients with neovascular age-related macular degeneration: a systematic literature review. Retina. 2022;42(4):589\u2013606.","journal-title":"Retina"},{"key":"1163_CR34","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/OPTH.S424315","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB. One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:2201\u20138.","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"1163_CR35","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen S-J, Chen Y, Guymer R, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131(8):914\u201326.","journal-title":"Ophthalmology"},{"key":"1163_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/aos.16797","volume":"103","author":"A Arnold-Vangsted","year":"2024","unstructured":"Arnold-Vangsted A, Schou MG, Balaratnasingam C, Cehofski LJ, Chhablani J, van Dijk EHC, et al. Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis. Acta Ophthalmol. 2024;103:247\u201356.","journal-title":"Acta Ophthalmol"},{"issue":"12","key":"1163_CR37","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1007\/s00417-024-06582-y","volume":"262","author":"Y Fukuda","year":"2024","unstructured":"Fukuda Y, Notomi S, Shiose S, Maehara Y, Kiyohara K, Fujiwara K, et al. Three-month outcomes of treatment with faricimab or aflibercept for neovascular age-related macular degeneration: a propensity score matching study in a Japanese population. Graefes Arch Clin Exp Ophthalmol. 2024;262(12):3971\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1163_CR38","doi-asserted-by":"publisher","first-page":"1346322","DOI":"10.3389\/fopht.2023.1346322","volume":"3","author":"FNI Ibrahim","year":"2023","unstructured":"Ibrahim FNI, Teo KYC, Tan TE, Chan HH, Chandrasekaran PR, Lee SY, et al. Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population. Front Ophthalmol (Lausanne). 2023;3:1346322.","journal-title":"Front Ophthalmol (Lausanne)"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01163-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01163-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01163-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:32:08Z","timestamp":1757179928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01163-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01163-6","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yen-An Lai, Mei-Chi Tsui, Shuo-Fang Cheng, Yi-Ting Hsieh, Tso-Ting Lai, Yun Hsia, Shih-Wen Wang, I-Hsin Ma, Kuo-Chi Hung, Chang-Pin Lin, Chang-Hao Yang, Chung-May Yang, and Tzyy-Chang Ho declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the Institutional Review Board of National Taiwan University Hospital (IRB no. 202409067RINA). The protocol and the waiver of informed consent for retrospective collection of medical records (from 1 January 2014 to 31 August 2024) were approved by the Research Ethics Committee A of NTUH.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}